Showing results (111-120 of 210) with videos related to

Sort By:
Pageof 21
Blood Advances|November 9, 2020
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myelomaThierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, et al.
The Lancet. Oncology|December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Haematologica|May 13, 2017
Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantationMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2018
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, J Christine Ye, Alan Howard, et al.
Oncotarget|February 5, 2017
A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigensLinus Backert, Daniel Johannes Kowalewski, Simon Walz, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple MyelomaKatja Weisel, Amrita Krishnan, Jordan M Schecter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2022
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple MyelomaAnita D'Souza, Nina Shah, Cesar Rodriguez, et al.
The New England Journal of Medicine|August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaAntonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.
Ejhaem|July 18, 2022
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myelomaThomas Martin, Amrita Krishnan, Kwee Yong, et al.
Leukemia|September 8, 2020
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapseMeletios Dimopoulos, Katja Weisel, Philippe Moreau, et al.
Pageof 21